The January/February issue of NeuroPerspective for 2015 has now been published, The issue is our annual overview of the neurotherapeutics sector, with capsule reviews for 107 CNS space companies of all sizes, a review of deal and funding trends; and Highlights and Lowlights from 2014, as well as an assessment of major events coming up this year. We include candid commentary about a wide range of issues pertinent to the development of therapeutics for neurology and psychiatry, including the bizarrely binary outcomes for nicotinic alpha7 modulators; Otsuka’s acquisition of Avanir; the thirteen neuro IPOs of 2014; Auspex’s surprising degree of success in HD; Biogen-Idec’s missteps vis-a-vis BIIB037; and many more topics.
Read More